miraDry Winner of the 2014 Pinnell Award for Product Innovation” - UK Aesthetic Awards 2014
08 December 2014
Winner of the 2014 Pinnell Award for Product Innovation, miraDry uses precisely controlled electromagnetic energy to significantly reduce underarm sweat. The judging panel were particularly impressed by the consistent results it has achieved for over 20,000 patients.
Tragara Reports Interim Results of Phase 1b Study of TG02 and Carfilzomib in Multiple Myeloma
06 December 2014
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy.
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2014 Financial Results
24 November 2014
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today provided a business update and announced its financial results for the third quarter ended September 30, 2014.
18 November 2014
Epic Sciences will present data describing the detection of clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood. The poster presentation will take place on November 20 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
Epic Sciences Appoints Toni Wayne as Vice President of Human Resources
13 November 2014
Strategic leader in aligning human resources management with business objectives and operations joins Epic's fast-paced, rapid-growth team.
12 November 2014
Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Because tumor biopsy material is often limited in lung cancer patients, Epic developed a new assay that detects PD-L1 protein on CTCs in a blood sample.
Epic Sciences Appoints Michael Giske as Chief Information Officer
21 October 2014
Epic Sciences announced the appointment of Michael Giske as chief information officer. Mr. Giske has more than 25 years of defining, designing and implementing secure, global, large-scale technology solutions to deliver innovative and impactful products. At Epic, he will lead the IT strategy and execution for the company’s diagnostics platform, which includes Epic’s circulating tumor cell (CTC) technology.
15 October 2014
Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis. In the phase 1/2 clinical study, eight patients diagnosed with non-infectious uveitis at three U.S. study centers received a single suprachoroidal injection of a formulation of preservative-free triamcinolone acetonide injectable suspension using Clearside’s proprietary microinjector.
Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance
15 September 2014
Epic Sciences announced today the appointment of Glen Paul Freiberg, RAC as vice president of regulatory affairs and quality assurance. Mr. Freiberg has more than 35 years of FDA-related experience and is recognized as a key leader in successful regulatory and compliance strategies for diagnostic products. Epic’s circulating tumor cell (CTC) technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy, selection and early drug resistance detection to improve the treatment of cancer.
04 September 2014
Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S. Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024